Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631744 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04631744: Clinical Trial Phase 2 study, sponsored by Weill Medical College of Cornell University.
NCT04631744 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04631744, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Primary Outcome
Radiographic progression will be assessed based on PCWG-modified RECIST 1.1 criteria for soft-tissue lesions and protocol-specific criteria for bone lesions. Progressive disease (PD) for soft-tissue lesions is defined as an increase ≥ 20% in the sum of the longest diameter (LD) of all target lesions based on the smallest sum LD since treatment started, or the appearance of one or more new lesions, or the appearance of new lesions. Progressive disease (PD) criteria for bone lesions is assessing w
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2025-11-09 |
| Phase | Phase 2 |
Why NCT04631744 stopped before completion
NCT04631744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT04631744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04631744 about?
NCT04631744 is a clinical study titled "Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)". The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRP...
What is the current status of trial NCT04631744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-03-03. Estimated completion is 2025-11-09.
What interventions are being tested in trial NCT04631744?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04631744?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04631744's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI